Daily Medication Pearl: Pitavastatin (Livalo)

Livalo is an HMG-CoA reductase inhibitor indicated as an adjunct to diet in adults with primary hyperlipidemia or mixed dyslipidemia.

Pearl of the day medication: Pitavastatin (Livalo)

Indication: Livalo is an HMG-CoA reductase inhibitor indicated as adjunctive therapy to diet in adults with primary hyperlipidemia or mixed dyslipidemia to reduce elevations in total cholesterol (TC), lower lipoprotein cholesterol density (LDL-C), apolipoprotein B (Apo B), triglycerides (TG) and to increase high density lipoprotein cholesterol (HDL-C).

Insight:

  • Dosage:The recommended starting dose for pitavastatin is 2 mg once daily.
  • Dosage forms: 1 mg, 2 mg and 4 mg tablets
  • Adverse events:The most common adverse reactions (≥2%) were myalgia, back pain, diarrhoea, constipation and pain in extremity.
  • Action mechanism:Pitavastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a rate-limiting step in the cholesterol biosynthesis. As a result, LDL receptor expression followed by LDL uptake from the blood to the liver is accelerated and plasma TC decreases. Sustained inhibition of cholesterol synthesis in the liver also decreases very low density lipoprotein levels.

Reference

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022363s015lbl.pdf

Comments are closed.